As published previously [27], the majority of melanoma cell lines resistant to either vemurafenib or trametinib exerted reduced MITF-M transcript and protein at the bulk levels, and the percentages of MITF-positive cells were also substantially lower in drug-resistant than in drug-naïve cell populations, which is summarized in Figure 1C. This might indicate that other than MITF-dependent program is executed more efficiently in resistant cells. The gene discussed is MITF; the disease is melanoma.